This is a StreetInsider.com Premium Only Page

(PHAT) – Business Wire

Mar 16, 2022 05:00 AM Frazier Life Sciences Closes $987 Million Venture Fund to Invest in Companies Developing Novel Biopharmaceuticals

Jul 12, 2021 08:00 AM Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership

Jan 7, 2021 08:00 AM Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

Jan 6, 2020 08:30 AM Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer

Dec 23, 2019 08:30 AM Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection

Dec 2, 2019 08:30 AM Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition

Dec 2, 2019 08:30 AM Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis

Nov 26, 2019 08:30 AM Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference

Nov 25, 2019 08:30 AM Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 13, 2019 04:05 PM Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference

Oct 29, 2019 04:05 PM Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Oct 24, 2019 08:25 PM Phathom Pharmaceuticals Announces Pricing of Initial Public Offering